Trial of Screening for ALOA-IgG AtheroAbzyme Test
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It plans to enroll 100 participants.
Also called NCT01272986
- Study
- In this atlas
Overview
- Design
- Interventional study; non-randomized; no masking; primary purpose diagnostic
- Phase
- Phase 3
- Enrolled
- 100 participants
- Sponsor
- Registry
-
NCT01272986
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Lebanon
- Registry status
- Completed
Technical summary
Registry record NCT01272986. Non-randomized; no masking; primary purpose diagnostic. Start 2011-01 (registry gives no type); primary completion 2011-03 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Trial of Screening for ALOA-IgG AtheroAbzyme Test
- Acronym
- OP512011
- Condition
- Myocardial Ischemia
- Condition
- Acute Coronary Syndrome
- Intervention (Device)
- ALOA IgG-Elisa
- Intervention (Device)
- ALOA IgG-AtheroAbzyme
- Lead sponsor
- Omicron Pharmaceuticals
Record details
- Record id
cardio:ct-nct01272986- Content hash
0a74486471cf4a94a3570604c1be864c33693fc759abcaa92854eb3edf2e39aa